RayThera

RayThera

Breakthrough small molecule therapies addressing critical unmet needs in immunology.

HQ location
San Diego, United States
Enterprise value
$440—660m
  • Edit
DateInvestorsAmountRound
*

$110m

Series A
Total Funding000k
Notes (0)
More about RayThera
Made with AI
Edit

RayThera is a small molecule drug discovery company focused on developing therapies for immunological diseases with significant unmet medical needs. Founded in August 2023, the company leverages decades of drug discovery expertise to accelerate the development of safer and more effective therapeutics. RayThera operates in the pharmaceutical and biotechnology market, targeting healthcare providers and patients requiring advanced treatment options for immunological conditions. The business model centers on research and development, progressing from target identification to clinical trials, with revenue generated through partnerships, licensing agreements, and eventual product sales. The company's approach is characterized by a nimble and adaptable development process, ensuring rigorous standards are maintained throughout. RayThera collaborates with clinical trial partners to ensure compliance with global privacy and data protection regulations. Keywords: small molecule, drug discovery, immunology, therapeutics, clinical trials, healthcare, pharmaceutical, biotechnology, development, partnerships.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads